Fundamental Analysis of REGENCELL BIOSCIENCE HOLDING(NASDAQ:RGC) stock

Fundamental Rating

Taking everything into account, RGC scores 3 out of 10 in our fundamental rating. RGC was compared to 193 industry peers in the Pharmaceuticals industry. While RGC has a great health rating, there are worries on its profitability. RGC has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

RGC had negative earnings in the past year.

In the past year RGC has reported a negative cash flow from operations.

In the past 5 years RGC always reported negative net income.

In the past 5 years RGC always reported negative operating cash flow.

1.2 Ratios

RGC's Return On Assets of -58.95% is on the low side compared to the rest of the industry. RGC is outperformed by 65.97% of its industry peers.

RGC's Return On Equity of -61.85% is in line compared to the rest of the industry. RGC outperforms 50.79% of its industry peers.

		Industry Rank	Sector Rank
ROA	-58.95%
ROE	-61.85%
ROIC	N/A

ROA(3y)-161.64%

ROA(5y)-161.25%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

RGC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, RGC has about the same amount of shares outstanding.

There is no outstanding debt for RGC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

RGC has an Altman-Z score of 62.23. This indicates that RGC is financially healthy and has little risk of bankruptcy at the moment.

RGC's Altman-Z score of 62.23 is amongst the best of the industry. RGC outperforms 97.91% of its industry peers.

RGC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	62.23

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 19.05 indicates that RGC has no problem at all paying its short term obligations.

RGC has a Current ratio of 19.05. This is amongst the best in the industry. RGC outperforms 91.62% of its industry peers.

RGC has a Quick Ratio of 19.05. This indicates that RGC is financially healthy and has no problem in meeting its short term obligations.

RGC's Quick ratio of 19.05 is amongst the best of the industry. RGC outperforms 91.62% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	19.05
Quick Ratio	19.05

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

RGC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -321.43%.

EPS 1Y (TTM)-321.43%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-172.73%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

RGC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

RGC does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

REGENCELL BIOSCIENCE HOLDING

NASDAQ:RGC (12/20/2024, 8:00:01 PM)

4.92

-0.31 (-5.93%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)N/A N/A

Earnings (Next)12-13 2022-12-13/bmo

Inst Owners0.06%

Inst Owner Change3119.72%

Ins Owners81.16%

Ins Owner Change0%

Market Cap64.01M

Analysts63.4

Price TargetN/A

Short Float %1.8%

Short Ratio0.19

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	5.32
P/tB	5.32
EV/EBITDA	N/A

EPS(TTM)-0.59

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-0.38

FCFYN/A

OCF(TTM)-0.38

OCFYN/A

SpS0

BVpS0.92

TBVpS0.92

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-58.95%
ROE	-61.85%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-161.64%

ROA(5y)-161.25%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	10.34%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	19.05
Quick Ratio	19.05
Altman-Z	62.23

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)176.78%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-321.43%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-172.73%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-335.43%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y17.52%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y5.88%

OCF growth 3YN/A

OCF growth 5YN/A

REGENCELL BIOSCIENCE HOLDING (RGC)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens